artículo científico
Three-finger toxins from the venom of Micrurus tschudii (desert coral snake): isolation and characterization of tschuditoxin-I
Fecha
2019Registro en:
0041-0101
10.1016/j.toxicon.2019.06.023
741-B7-608
Autor
Lomonte, Bruno
Camacho Umaña, Erika
Fernández Ulate, Julián
Salas Arruz, María
Zavaleta Martínez Vargas, Alfonso
Institución
Resumen
Venoms from Micrurus (New World coral snakes) display potent peripheral neurotoxicity which may cause death
by respiratory paralysis, yet many are poorly or not characterized. The major venom components of coral snakes
are three-finger toxins (3FTxs) and phospholipases A2, whose proportions vary among species. As a trend, venoms
of Micrurus from South America contain high proportions of 3FTxs, in contrast to most North and Central
American species. Micrurus tschudii tschudii, the ‘Desert coral snake’ from Perú, displays an extreme 3FTx-predominant
venom phenotype, with ∼95% of its proteome belonging to this protein family. This study evaluated
the toxicity of its major 3FTxs in mice. A lethal 3FTx, here named tschuditoxin-I, was purified and sequenced by
MALDI-TOF-TOF and N-terminal degradation. Tschuditoxin-I showed highest similarity to MS-1, a short-chain α-
neurotoxin from the aquatic, fish-eating coral snake M. surinamensis. The single amino acid substitution between
these two toxins maps at the tip of the first β-stranded ‘finger’ in the modeled structure of tschuditoxin-I, suggesting
it may have a role in interaction with its target, which remains to be investigated. Owing to its lethal
action, tschuditoxin-I is likely to be medically relevant in envenomings. In spite of its 74% sequence identity
with an α-neurotoxin of M. nigrocinctus, an equine antivenom raised against venom of the latter did not immunorecognize
tschuditoxin-I or M. t. tschudii venom by ELISA. This underscores the need of characterizing the
biochemical and immunological properties of the main toxic components of Micrurus venoms, aiming to improve
the limited para-specific coverage of current antivenoms.